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Early Breast Cancer
Therapy and Cardiovascular Injury
Lee W. Jones, PHD,* Mark J. Haykowsky, PHD,‡ Jonas J. Swartz, BS,* Pamela S. Douglas, MD,†
John R. Mackey, MD§
Durham, North Carolina; and Edmonton, Alberta, Canada
Although recent advances in curative-intent therapies are beginning to produce significant survival gains in early
breast cancer, these improvements may ultimately be attenuated by increased risk of long-term cardiovascular
mortality. This paper reviews emerging evidence on the cardiovascular effects of breast cancer adjuvant therapy
and proposes a new entity that we have labeled the “multiple-hit” hypothesis. The evidence that lifestyle modifi-
cation, especially exercise therapy, may mitigate these adverse effects is also reviewed. These issues are of con-
siderable practical importance for cardiovascular clinicians, as identification and intervention in those at high
risk for cardiovascular complications may reduce a major cause of mortality in women with early breast
cancer. (J Am Coll Cardiol 2007;50:1435–41) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.06.037a
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treast cancer is the most common malignancy in American
omen, with approximately 213,000 new cases diagnosed in
006 (1). Although the incidence of breast cancer has
ncreased by 0.2% per year between 1997 and 2000, im-
rovements in detection and therapy have resulted in
ignificant survival gains with breast cancer-specific mortal-
ty decreasing almost 24% between 1990 and 2000. As a
esult, approximately 2.3 million American women are now
iving with a previous history of breast cancer, with sufficient
urvival to be at risk for cardiovascular disease (CVD). The
urpose of this paper is to review the cardiovascular effects
f current and forthcoming adjuvant therapies for the
reatment of early breast cancer so that clinicians will be
etter able to care for this emerging cohort of new cardio-
ascular patients. We also review the evidence supporting
he potential treatment efficacy of conventional cardiovas-
ular risk factors with both drugs and lifestyle modifications,
ncluding exercise therapy, to mitigate and/or prevent
herapy-induced CVD in this population.
arly Breast Cancer Patients:
Population at Risk for CVD at Diagnosis
he association between traditional risk factors and CVD
as been well studied among women in the general popu-
ation. For example, an analysis of the Framingham data (2)
stimated a 39% lifetime risk of developing CVD in women
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niversity Medical Center, Durham, North Carolina; and the ‡Faculty of Rehabil-
tation Medicine and §Faculty of Medicine, Division of Medical Oncology, Cross
ancer Institute, University of Alberta, Edmonton, Alberta, Canada.a
Manuscript received April 11, 2007; revised manuscript received May 24, 2007,
ccepted June 3, 2007.t age 50 years. At this age, 40% of women in the
opulation had at least 1 existing risk factor, and 17% had
or more risk factors, the latter associated with a 50%
ifetime CVD risk. The presence of diabetes at age 50 years
n either gender confers the highest lifetime risk for CVD of
ny single risk factor, with a CVD risk in women to age 75
ears of 57% (2). These findings were confirmed by recent
ata from the Chicago Heart Association Detection Project
n Industry, which found that, in comparison with women
ith favorable CVD risk profile, those with 3 risk factors
ad a substantially greater risk of CVD-related mortality
3). On the basis of this evidence, it is likely that a
ubstantial fraction of breast cancer patients, at the time of
iagnosis, will have a significant risk of developing CVD,
hich is then added to by the direct and indirect effect of
reast cancer treatment. Importantly, as reviewed in this
aper, the presence of pre-existing CVD risk factors is itself
strong predictor for the development of therapy-induced
ardiovascular injury, making the likely lifetime risk for
VD much greater.
Indeed, although many factors have been associated with
primary breast cancer diagnosis, other established but
esser-known risk factors are physical inactivity and obesity.
ecent estimates suggest that physical inactivity confers a
opulation-attributable risk of breast cancer among white
omen of 2% to 15% (4), with overweight and obesity being
ssociated with a 34% and 63% increased breast cancer risk,
espectively (5). It could be speculated, therefore, that
hysical inactivity and obesity rates may be even greater
mong early breast cancer patients that, in turn, may
ranslate into greater CVD risk independent of the effects of
djuvant therapy. Irwin et al. (6) reported that 62% of breast
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weight or obese, whereas Jones
et al. (7) reported that 36% are
sedentary. Both estimates are
similar to those reported for
women in the general U.S. pop-
ulation. Clearly, further research
is required to estimate the rela-
tive proportion of cardiovascular
morbidity/mortality attributable
to either lifestyle modification
and/or adjuvant therapy among
women with early breast cancer.
Early Breast Cancer
Therapy Selection
Although the broad range of car-
iovascular diseases reflects complex interactions between
raditional and novel risk factors, the situation is further
omplicated by the use of adjuvant therapy. Such therapies
re selected on the basis of a complex algorithm, including
atient factors (age, comorbidities, physiologic status, and
atient preference) and tumor factors (tumor size, lymph
ode involvement, histological grade, and estrogen receptor
ER] and human epidermal growth factor receptor [HER]-
status) (8). For example, women at low risk of recurrence
ho have ER-positive tumors may be offered oral hormonal
herapy with tamoxifen or aromatase inhibitors. Women at
oderate risk of recurrence generally are recommended to
ndergo 3 to 6 months of anthracycline-based chemother-
py, with or without adjuvant taxanes, and when ER-
ositive disease is diagnosed, adjuvant hormonal therapy.
omen at high or extremely high risk of recurrence are
ecommended anthracycline-taxane chemotherapy, locore-
ional radiotherapy, followed by hormone therapy if ER
ositive. Additionally, for the 25% of women whose tumors
ossess the HER-2 alteration, 1 year of adjuvant trastuzumab
s recommended either with, or after, chemotherapy (8).
ardiovascular Complications
f Breast Cancer Therapy
n the following sections, we review the available evidence
escribing the cardiovascular effects of current and forth-
oming early breast cancer therapies (i.e., polychemo-
herapy, radiotherapy, endocrine therapy, HER-2–directed
herapies, angiogenesis inhibition) and briefly review the
ostulated biological mechanisms that may underlie
herapy-associated cardiovascular injury.
olychemotherapy. Unfortunately, each of the many che-
otherapeutic agents used in breast cancer management is
ssociated with unique acute and long-term cardiac compli-
ations (Table 1). Although the majority of complications
re transient effects that do not persist after completing
Abbreviations
and Acronyms
ACEI  angiotension-
converting enzyme inhibitor
CVD  cardiovascular
disease
EPC  endothelial
progenitor cell
ER  estrogen receptor
HER  human epidermal
growth factor receptor
HF  heart failure
LVEF  left ventricular
ejection fraction
ROS  reactive oxygen
specieshemotherapy, use of anthracycline-containing regimens (i.e., roxorubicin, epirubicin) is well recognized to trigger dose-
ependent, cumulative, progressive cardiac dysfunction mani-
ested as decreased left ventricular ejection fraction (LVEF),
nd ultimately, symptomatic congestive heart failure (HF).
On the basis of the classic data by Von Hoff and associates
9), most treatment protocols limit the cumulative dose of
oxorubicin to 450 to 550 mg/m2. The incidence of HF in
odern adjuvant trials is typically between 0% and 1.6%
ith incidence rates reaching 2.1% in patients receiving
oxorubicin with sequential paclitaxel (10). Epidemiologic
vidence suggests that, even without an overt decline in
jection fraction at the time of treatment, receiving
nthracycline-based adjuvant chemotherapy carries a sub-
tantial long-term risk of HF, especially for women older
han 65 years of age (11).
Although adjuvant trials typically report only symptom-
tic cardiac events, recent prospective studies report fre-
uent subclinical left ventricular dysfunction, defined as an
bsolute decrease in LVEF of 10% U, in 10% to 50% of
atients receiving anthracyline-based therapy (12). The
ong-term consequences of subclinical LV dysfunction are
ot known, although this permanent damage leaves the
atient more susceptible to recurrent progressive dysfunc-
ion associated with aging and other disease etiologies. In
ddition to cumulative dose, the route of drug administra-
ion, delivery schedule, co-administered drugs, patient age,
resence of CVD risk factors, and cardiac radiation all
nfluence the development of cardiac dysfunction (13). The
iological mechanisms underlying chemotherapy-associated
ardiac dysfunction remain to be fully elucidated. Genera-
ion of reactive oxygen species (ROS) and induction of
ardiac myocyte apoptosis are hypothesized to play a central
ole. Furthermore, ROS may continue to be produced by
drug retained within myocytes contributing to late-
ccurring cardiovascular injury (14).
adiotherapy. Recognition of the adverse cardiac effects of
lder radiotherapy techniques led to the development of
lternative approaches such as intensity modulated radio-
herapy and 3D-based conformal tomography that deliver
ore diverse radiation doses and fraction sizes that mini-
ize heart and lung exposure. Hooning et al. (15) examined
he long-term CVD risk according to specific radiation
elds and interaction with known CVD risk factors among
,414 10-year survivors of breast cancer treated from 1970
hrough 1986 in the Netherlands. After 18 years’ median
ollow-up, 62.9 excess cases per 10,000 patient years of CV
vents were observed compared with the general female
opulation. In addition, radiotherapy to either the left or
ight side of the internal mammary chain was associated
ith increased CVD for 1970 to 1979 compared with
atients who received no radiotherapy. After 1979, radi-
tion in combination with chemotherapy was associated
ith a greater risk of HF than patients who received
adiotherapy only. Finally, when combined, smoking and
adiotherapy were associated with an additive effect on
isk of myocardial infarction (15). Giordano et al. (16)
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October 9, 2007:1435–41 Early Breast Cancer Therapy and Cardiovascular Injuryeported that for women diagnosed and treated between
973 and 1979, the 15-year CVD mortality rate was
ignificantly greater for left-sided versus right-sided tumors
13% vs. 10.2%). There were no significant differences for
omen diagnosed and treated after 1984 with newer radio-
herapy techniques. Other studies have reported similar
Potential Short-Term and Long-TermCardiov scular Risks of Adjuvant Breast Cancer
Table 1 Potential Short-Term and Long-TermCardiovascular Risks of Adjuvant B
Adjuvant Therapy Polychemotherapy S
Anthracyclines Atrial and v
Pericarditis
Reduced ej
cardiomy
Alkylating agents
Cisplatin Myocardial
Hypertensio
Heart failur
Arrhythmias
Heart block
Endocardia
Cyclophosphamide Pericarditis
Heart failur
Atrial ectop
Bradycardia
Microtubule-targeting drugs
Taxanes Bradycardia
Atrial and v
Heart failur
Myocardial
Antimetabolites
Fluorouracil Heart failur
Atrial or ven
Myocardial
Capecitabine Heart failur
Atrial or ven
Myocardial
Methotrexate Arrhythmias
Myocardial
Radiotherapy
Angina
Dyspnea
Heart failur
Diffuse intim
arteries/
Pericardial
Sudden dea
Endocrine therapy*
Tamoxifen Venous thro
Aromatase inhibitors Unknown a
HER-2–directed therapies*
Trastuzumab Left ventric
Heart failur
Angiogenesis inhibitors*
Bevacizumab (not yet evaluated in the
adjuvant breast cancer setting)
Hypertensio
Myocardial
Left ventric
Venous thro
Stroke
Heart failur
Angina
*The time-course (early vs. late effects) of cardiovascular risk asso
(HER)-2–directed therapies, and angiogenesis inhibitors has not been
been used in early breast cancer management.ndings (17). 6Although modern radiation techniques provide lower
ardiac mortality risks than older techniques, cardiopulmo-
ary damage does nonetheless occur. Prospective studies
eport cardiac perfusion defects in 50% to 63% of women
nd radiologic evidence of irreversible lung fibrosis and
ssociated pulmonary disorders with left-sided breast cancer
emic Therapy
Cancer Systemic Therapy
rm Effects Long-Term Effects
lar arrhythmias
arditis
fraction,
y, death
Progressive decrease in left
ventricular function, often
leading to overt heart
failure
ia/infarction
is
arditis
ventricular block
lar arrhythmias
ia
r ectopy
ia/infarction
r ectopy
ia/infarction
ia/infarction
perplasia of coronary
ain stenosis
n
Coronary artery disease
Pericardial constriction
Atherosclerosis
Mediastinal fibrosis
Carotid lesions
Thickening of the pericardium
Valvular heart disease
s
ime
sfunction
ion
sfunction
s
with endocrine therapy, human epidermal growth factor receptor
shed given the relatively short period of time that these agents haveSyst
reast
hort-Te
entricu
/myoc
ection
opath
ischem
n
e
l fibros
/myoc
e
y
/atrio
entricu
e
ischem
e
tricula
ischem
e
tricula
ischem
ischem
e
al hy
left m
effusio
th
mbosi
t this t
ular dy
e
n
infarct
ular dy
mbosi
e
ciatedto 24 months after radiotherapy (18,19).
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Early Breast Cancer Therapy and Cardiovascular Injury October 9, 2007:1435–41Risk factors for radiation-induced cardiovascular morbidity
nd mortality go beyond the myocardial and/or pulmonary
olume in the field and the dose delivered to that field
dose-volume histogram), to include the presence of pre-existing
VD risk factors and use of anthracyclines (20). Again, the
eneration of ROS is thought to play a major role (21).
ndocrine therapy. Traditional endocrine therapy (tamox-
fen, oophorectomy) for women with hormone receptor-
ositive breast cancer has not been clearly associated with
ardiovascular injury. Although tamoxifen may have cardio-
rotective properties, these favorable benefits appear to be
ffset by a greater incidence of venous thromboembolic
vents (22). Seminal results have demonstrated the superi-
rity of third-generation aromatase inhibitors (AIs) used
nstead of or after 2 to 3 years or 5 years of tamoxifen in
arly breast cancer (23). However, the marked reduction in
erum estrogen associated with AI therapy raises concerns
bout the adverse cardiovascular effects of these agents. In
omparison with tamoxifen, AIs have been associated with
ore CVD events although the incidence of thromboem-
olic events was significantly lower. Thus, longer-term
ollow-up is required to fully assess the associated cardio-
ascular risks.
ER-2–directed therapies. The addition of trastuzumab,
Herceptin), a humanized monoclonal antibody against
ER2, to standard adjuvant chemotherapy is associated with
mproved disease-free and overall survival in HER-2/neu-
ositive early breast cancer (24,25). However, HER-2–
irected therapies are associated with cardiac toxicity, with HF
ncidence between 2.0% and 4.1%. The corresponding rates of
symptomatic cardiac dysfunction range between 3.0% and
8.0% (24,25). Contributing factors include poor baseline
unction, reduced post-standard chemotherapy LVEF, age at
tudy entry, and previous or concurrent treatment with doxo-
ubicin (26). Finally, it is important to note that the current
ollow-up in all adjuvant trials is relatively short (3 years), and
he long-term cardiac effects of these trastuzumab-based strat-
gies remain unknown.
Elegant preclinical studies have demonstrated that erbB2
nd its associated ligands, neuregulins, are essential for
ardiac structure and function whereas deletion of this gene
eads to dilated cardiomyopathy (27). Other in vitro and
n vivo work also has suggested that suppression of erbB2
ay accelerate the net breakdown of sacromere proteins
nduced initially by anthracyclines leading to diastolic and
ystolic dysfunction.
nhibition of angiogenesis. Vascular endothelial growth
actor and other proteins implicated in tumor angiogenesis and
urrounding tumor vasculature have become attractive thera-
eutic targets because of their critical role in tumor growth and
etastases (28). With the demonstrated efficacy of angiogen-
sis inhibitors (e.g., bevacizumab, sorafenib, sunitinib) and the
romising role of newer vascular disrupting agents (ZD6126,
ZT-1027, ABT-751), trials are underway in early breast
ancer. However, these agents are already known to be asso-
iated with cardiovascular complications, with reports of arte- pial thromboembolic events, increase in cardiac troponin, re-
uctions in LVEF and, most commonly, hypertension (29).
Decreased nitric oxide production and bioavailability is
ostulated to play a major role in angiogenesis inhibition-
ssociated cardiovascular injury (30). Nitric oxide influences a
umber of biological processes implicated in hypertension
ncluding decreased renal sodium excretion, endothelial nitric
ynthase and circulating endothelial progenitor cells (EPCs) (30).
nfavorable lifestyle changes. Physical activity and body
eight are 2 major independent risk factors for CVD that
re often neglected when evaluating cardiovascular conse-
uences of breast cancer adjuvant therapy. Irwin et al. (31)
eported that, on average, early breast cancer patients
ecreased their physical activity by 2 h/week from before to
fter diagnosis, with greater decreases among women re-
eiving combined treatment as compared with single-
odality adjuvant therapy. Furthermore, 70% of breast
ancer patients gain between 2.5 to 6.2 kg of body weight
uring adjuvant therapy (32). Although physical inactivity
nd weight gain are strong independent predictors of
ardiovascular mortality in noncancer adult populations, the
linical value of these factors to predict an elevated CVD-
pecific morbidity and mortality in breast cancer remains to
e determined.
he “Multiple-Hit” Hypothesis
s demonstrated, women diagnosed with early breast cancer
re already at risk for CVD, and virtually all adjuvant therapies
re associated with unique and varying degrees of cardiovascu-
ar injury. Thus, as women progress through the selected
reatment regimens, they will be subjected to a series of
equential or concurrent cardiovascular insults coupled with
ifestyle perturbations that collectively leave patients with overt
r sub clinical CVD. At a minimum, these insults enhance
usceptibility to further cardiovascular injury and, ultimately,
isk of premature CVD mortality. We have labeled this
henomenon the “multiple-hit” hypothesis (Fig. 1).
Unfortunately, currently few data are available to support
he contention of the “multiple hit.” The prevalence of
VD risk factors has not been collected either prospectively
r retrospectively among early breast cancer patients after
odern adjuvant therapy. Hooning et al. (15) reported that
2%, 26%, 10%, and 9% of women treated with radiother-
py were smokers, had hypertension, hypercholesterolemia,
nd diabetes mellitus, respectively. These data were, how-
ver, for women treated between 1970 through 1986 and
ot likely to reflect current risk factor prevalence. As such,
t is not yet possible to estimate the CVD risk among early
reast cancer patients simply by adding the potential disease
urden of adjuvant therapy to the CVD estimates from the
eneral population. Future, large-scale, prospective studies
o comprehensively evaluate CVD risk burden associated
ith modern adjuvant therapy are urgently required. As an
nitial step toward this goal, our group recently completed 2
ilot studies evaluating cardiovascular risk profiles using a
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October 9, 2007:1435–41 Early Breast Cancer Therapy and Cardiovascular Injuryide range of established and novel CVD risk factors
mong early breast cancer patients following completion of
rimary therapy. Overall, in comparison to age/gender-
atched controls, breast cancer patients had a significantly
orse cardiovascular risk profile, thus supporting our con-
ention of the “multiple hit” (33,34).
Although the current and future consequences of the
multiple-hit” hypothesis will be clinically devastating, it is
urrently not possible to predict which patients are at
ncreased risk of late-occurring CVD. Current monitoring
echniques (e.g., echocardiography, radionuclide angiogra-
hy) have limited ability to detect early cardiac damage (35).
n response, the utility of sensitive imaging modalities (i.e.,
ingle-photon emission computed tomography, magnetic
esonance imaging; exercise or dobutamine stress testing) as
ell as novel biochemical markers (brain natriuretic peptide,
roponin I) that allow more accurate detection and quanti-
cation of subclinical cardiac damage have been explored.
or example, Cardinale et al. (36) demonstrated that in-
rease in troponin I was a strong predictor of LV dysfunc-
ion soon after chemotherapy among cancer patients.
reast Cancer and Cardiovascular Injury:
revention and/or Treatment Approaches
reventive and/or treatment strategies will be required to
efine and offset the acute and long-term clinical conse-
uences of the “multiple hit.” Unfortunately, it is not
urrently known whether treatment of risk factors modifies
VD incidence among women with breast cancer to the
ame extent as in general population. However, at least one
linical trial has examined the effects of angiotensin-
onverting enzyme inhibition (ACEI) on preventing cardiac
Figure 1 The “Multiple-Hit” Hypothesis
A schematic representation describing the “multiple-hit” hypothesis. At diagnosis,
heightened cardiovascular disease (CVD) risk factors, which increase the risk of a
pies used in breast cancer are associated with unique and varying degrees of dire
text of concomitant lifestyle perturbations (indirect effects) that combine to reduce
susceptible to further cardiovascular insults and at higher risk of premature deathysfunction among cancer patients. Based on their prior mork, Cardinale et al. (37) randomized patients who expe-
ienced an increase in troponin I shortly after chemotherapy
o receive an ACEI (enalapril) or usual care for 12 months.
esults indicated a significant reduction in LV function
mong usual care patients only (37). In a retrospective study,
wer et al. (38) reported that maximum-tolerated doses of
CEI and beta-blockers allowed therapy to be reinitiated
mong breast cancer patients who initially had treatment
iscontinued due to trastuzumab-induced heart failure. On
he basis of these findings and our own clinical experience,
reatment of risk factors consistent with the American
eart Asssociation guidelines for prevention of CVD in
omen (39) appears prudent. Effective strategies to preserve
V function are of major importance because therapy is
ithheld when LVEF decreases 50% and not resumed
ntil LVEF is 50%, which has obvious implications for
linical outcome of breast cancer patients.
Recommendations for the treatment of major risk factors
nclude optimal lifestyle behaviors in conjunction with
harmacotherapy, as required. Specifically, beta-blockers
nd/or ACEI, with the addition of other agents (e.g.,
hiazides), are recommended for the initial therapy of
ypertension. Regarding hypercholesterolemia, the use of
-hydroxy-3-methyl-glutaryl coenzyme A reductase inhib-
tors (statins) is recommended to achieve low-density li-
oprotein cholesterol 100 mg/dl. The use of sulfonylurea
r biguanide (metformin) is recommended for women with
ype II diabetes mellitus to achieve a glycosylated hemoglo-
in (HbA1c) 7% (39). Of note, exercise training may be
ffective in this setting because of its demonstrated effects on
ardiovascular reserve, individual risk factors, and overall
eductions in CVD mortality (40,41). Moreover, a recent
ificant proportion of early breast cancer patients present with pre-existing or
t therapy-associated cardiovascular injury. Independently, many adjuvant thera-
erse effects on the cardiovascular system. These direct effects occur in the con-
ovascular reserve. Collectively, these changes may leave the patient more
cardiovascular mortality.a sign
djuvan
ct adv
cardi
due toeta-analysis (42) reported that exercise training resulted in
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Early Breast Cancer Therapy and Cardiovascular Injury October 9, 2007:1435–41significant improvement in exercise capacity among
omen with early breast cancer while epidemiologic data
uggested that greater physical activity after therapy was
ssociated with decreased breast cancer-specific and all-
ause mortality (43). Only one study to date has examined
he effects of exercise training on CVD risk factors among
arly breast cancer patients (44).
There is also a paucity of data examining any adverse or
eneficial effects of recommended risk factor-modification
trategies on cancer outcomes. However, several preclinical
tudies have demonstrated that lipophilic statins (e.g., sim-
astatin, fluvastatin), ACEI, and metformin have antineo-
lastic activity in several experimental models of breast
arcinogenesis (45–47). On the basis of these promising
ata, several clinical trials are underway to investigate the
otential antitumor efficacy of these agents in breast cancer
atients. As a cautionary note, all preclinical studies have
xamined the potential efficacy of CVD medications with-
ut concurrent cancer therapy. Thus, little is known about
he potential interaction between these agents.
Pharmacologic CVD medications as well as lifestyle
pproaches (e.g., exercise training) influence a wide
pectrum of biological processes that may be particularly
elevant for the antineoplastic effects of cancer therapies.
or example, in addition to their vasodilatory effects,
CEI and exercise training are also potent antioxidants
nd actively scavenge ROS and lower oxidative stress
48). Because radiotherapy and certain cancer chemo-
herapeutics rely on ROS-mediated deoxyribonucleic
cid damage to induce apoptosis, one could speculate that
hese interventions might inhibit the efficacy of these
herapies. On the other hand, reduction in ROS oxidative
amage may confer protection against doxorubicin-induced
ardiac toxicity (48).
Similarly, statins and exercise therapy increase the pro-
uction, number, and function of circulating EPCs via
ascular endothelial growth factor-dependent mechanisms
49,50). Several reports have demonstrated that EPCs
ignificantly contribute to tumor angiogenesis (51); thus,
ne might speculate that interventions that induce EPC
ctivity would augment tumor growth. Paradoxically, how-
ver, preclinical studies have reported that statins and
xercise (without concurrent antitumor therapy) inhibit
stablished breast tumor growth and metastatic progression
52). Although strategies that improve overall global tumor
lood flow may improve the delivery and efficacy of anti-
ancer drugs in established breast tumors (53), in the
djuvant setting where treatment is directed at micrometas-
ases, the clinical relevance of these observations is un-
nown. Clearly, the use of any risk factor modification
trategy during early breast cancer therapy needs to be
igorously evaluated using appropriate end points (e.g.,
ardiac and cardiovascular function, adverse events, cancer
rug pharmacokinetics, and relapse-free survival).linical Implications
n middle-aged and elderly women who already are at risk for
VD, the direct and indirect effects of adjuvant therapy
oupled with an unhealthy lifestyle and presence of modifiable
isk factors all contribute to either overt CVD or an elevated
isk of future CVD in women with early breast cancer.
ardiovascular clinicians need to understand this risk and
iagnostic, preventive, and/or therapeutic strategies that effec-
ively address this need are urgently required. On the basis of
ur current understanding, we recommend that a formal
aseline CVD risk assessment, using either Framingham (54)
r Reynolds (55) risk scores, be performed before adjuvant
herapy. All women should be counseled about the value of a
ealthy lifestyle, and a program of individualized primary
revention should be undertaken as described in the American
eart Association guidelines (39). Unfavorable risk factors
hould to be managed, ideally before the initiation of adjuvant
herapy. Consideration should be given to more aggressive
anagement of risk factors than might otherwise be indicated,
n view of the “multiple-hit” hypothesis presented here, al-
hough further research would be required before making such
recommendation universal.
onclusions
ecent advancements in curative-intent therapies have led to
ramatic improvements in breast cancer-specific mortality but
t the direct expense of increased risk of cardiovascular-related
ortality. Evidence reviewed in this paper suggests that estab-
ished and forthcoming breast cancer adjuvant therapies are
ssociated with varying degrees of direct cardiovascular injury
n conjunction with significant indirect lifestyle changes that
oncomitantly reduce cardiovascular reserve, which we term
he “multiple hit.” We speculate that the consequences of the
multiple hit” will become an increasingly important issue in
he management of women with early breast cancer. Overall,
his information is of critical importance to cardiovascular
hysicians who will increasingly be called upon to evaluate and
reat these women.
eprint requests and correspondence: Dr. Lee W. Jones, Box
624, Duke University Medical Center, Durham, North Carolina
7710. E-mail: lee.w.jones@duke.edu.
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